Literature DB >> 8738259

Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease.

M A Smith1, S L Siedlak, P L Richey, R H Nagaraj, A Elhammer, G Perry.   

Abstract

In this study, we evaluate the ability of several solvents to solubilize insoluble paired helical filaments (PHF) of Alzheimer disease. Specifically, we use protein extraction and reduction in the volume of insoluble material as quantitative assays to establish solvents of PHF. Using sequential categories of protein solvent to analyze insoluble PHF, only alkali or exhaustive proteolysis are effective in completely solubilizing PHF, while a variety of denaturants are ineffective. Alkali does not affect the phosphorylation state of PHF and complete dephosphorylation of PHF with hydrofluoric acid does not affect PHF solubility. These findings suggest that the 'hyperphosphorylation' of PHF proteins is not responsible for PHF insolubility. However the in vitro glycation of tau generates PHF that are insoluble in SDS and soluble in alkali. These findings suggest that protein crosslinks, including advanced glycation endproduct-derived crosslinks which were recently described in Alzheimer disease, play a major role in effecting PHF insolubility in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738259     DOI: 10.1016/0006-8993(95)01473-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma.

Authors:  J E Donahue; T M Berzin; M S Rafii; D J Glass; G D Yancopoulos; J R Fallon; E G Stopa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover.

Authors:  Xiongwei Zhu; Rudy J Castellani; Paula I Moreira; Gjumrakch Aliev; Justin C Shenk; Sandra L Siedlak; Peggy L R Harris; Hisashi Fujioka; Lawrence M Sayre; Pamela A Szweda; Luke I Szweda; Mark A Smith; George Perry
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

Review 3.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

4.  Widespread peroxynitrite-mediated damage in Alzheimer's disease.

Authors:  M A Smith; P L Richey Harris; L M Sayre; J S Beckman; G Perry
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

Review 5.  Oxidative stress in diabetes and Alzheimer's disease.

Authors:  V Prakash Reddy; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.

Authors:  Tomas Smolek; Santosh Jadhav; Veronika Brezovakova; Veronika Cubinkova; Bernadeta Valachova; Petr Novak; Norbert Zilka
Journal:  Mol Neurobiol       Date:  2018-05-16       Impact factor: 5.590

7.  Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease.

Authors:  Sandra L Siedlak; Gemma Casadesus; Kate M Webber; Miguel A Pappolla; Craig S Atwood; Mark A Smith; George Perry
Journal:  Free Radic Res       Date:  2009-02

Review 8.  Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation.

Authors:  Carolina Alquezar; Shruti Arya; Aimee W Kao
Journal:  Front Neurol       Date:  2021-01-07       Impact factor: 4.003

9.  Estrogen receptor-α is localized to neurofibrillary tangles in Alzheimer's disease.

Authors:  Chunyu Wang; Fan Zhang; Sirui Jiang; Sandra L Siedlak; Lu Shen; George Perry; Xinglong Wang; Beisha Tang; Xiongwei Zhu
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.